Prognostic Impact of MYC Protein Expression in Central Nervous System Diffuse Large B-cell Lymphoma: Comparison with MYC Rearrangement and MYC MRNA Expression

Overview

Journal Mod Pathol

Specialty Pathology

Date 2016 Oct 1

PMID 27687005

Citations 11

Authors

Seung-Myoung Son

Sang-Yun Ha

Hae-Yong Yoo

Dongryul Oh

Seok-Jin Kim

Won-Seog Kim

Young-Hyeh Ko

Affiliations

Soon will be listed here.

Abstract

The prognostic role of MYC has been well documented in non-central nervous system diffuse large B-cell lymphoma; however, it remains controversial in central nervous system diffuse large B-cell lymphoma. To investigate the prognostic value of MYC, we analyzed the MYC protein expression by immunohistochemistry, mRNA expression by RNA in situ hybridization, and gene status by fluorescence in situ hybridization in 74 cases of central nervous system diffuse large B-cell lymphoma. Moreover, we examined the correlation between MYC translocation, mRNA expression, and protein expression. The mean percentage of MYC immunopositive cells was 49%. Using a 44% cutoff value, 49 (66%) cases showed MYC protein overexpression. The result of mRNA in situ hybridization using the RNA scope technology was obtained using the H-scoring system; the median value was 34.2. Using the cutoff value of 63.5, 16 (22%) cases showed MYC mRNA overexpression. MYC gene rearrangement was detected in five out of 68 (7%) cases. MYC translocation showed no statistically significant correlation with mRNA expression; however, all MYC translocation-positive cases showed MYC protein overexpression, with a higher mean percentage of MYC protein expression than that of translocation-negative cases (78 vs 48%, P=0.001). The level of MYC mRNA expression was moderately correlated with the level of MYC protein expression (P<0.001). The mean percentage of MYC protein expression in the high MYC mRNA group was higher than that in the low MYC mRNA group (70 vs 47%, P<0.001). A univariate analysis showed that age over 60 years, Eastern Cooperative Oncology Group (ECOG) performance status ≥2 and MYC protein overexpression were significantly associated with an increased risk of death. MYC translocation and MYC mRNA expression had no prognostic significance. On multivariate analysis, MYC protein overexpression and ECOG score retained prognostic significance.

Citing Articles

Association between microenvironment-related genes and prognosis of primary central nervous system lymphoma.

Hattori K, Makishima K, Suma S, Abe Y, Suehara Y, Sakamoto T EJHaem. 2024; 5(6):1201-1214.

PMID: 39691244 PMC: 11647707. DOI: 10.1002/jha2.1046.

Diagnostic and prognostic value of c-MYC gene expression in hematological malignancies.

Okafor I, Okoroiwu H, Ogar C Afr Health Sci. 2024; 23(2):265-273.

PMID: 38223598 PMC: 10782349. DOI: 10.4314/ahs.v23i2.30.

Impact of MYC and BCL2 double expression on outcomes in primary CNS lymphoma: a UK multicenter analysis.

Poynton E, Chernucha E, Day J, Prodger C, Hopkins D, Rakesh P Blood Adv. 2023; 8(7):1772-1775.

PMID: 38039509 PMC: 10985804. DOI: 10.1182/bloodadvances.2023011426.

The Bioinformatical Identification of Potential Biomarkers in Heart Failure Diagnosis and Treatment.

Sheng X, Jin X, Liu Y, Fan T, Zhu Z, Jin J Genet Res (Camb). 2022; 2022:8727566.

PMID: 35645616 PMC: 9126668. DOI: 10.1155/2022/8727566.

Clinical Outcomes of RTOG 9310 Protocol for Primary Central Nervous System Lymphoma: Single-Center Experience with 87 Patients.

Kim J, Kim T, Lee H, Kim S, Park J, Lee M Curr Oncol. 2021; 28(6):4655-4672.

PMID: 34898570 PMC: 8628744. DOI: 10.3390/curroncol28060393.

References

Valera A, Lopez-Guillermo A, Cardesa-Salzmann T, Climent F, Gonzalez-Barca E, Mercadal S . MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica. 2013; 98(10):1554-62. PMC: 3789460. DOI: 10.3324/haematol.2013.086173. View

Hans C, Weisenburger D, Greiner T, Gascoyne R, Delabie J, Ott G . Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2003; 103(1):275-82. DOI: 10.1182/blood-2003-05-1545. View

Snuderl M, Kolman O, Chen Y, Hsu J, Ackerman A, Dal Cin P . B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol. 2010; 34(3):327-40. PMC: 3152212. DOI: 10.1097/PAS.0b013e3181cd3aeb. View

Lim D, Kim W, Kim S, Yoo H, Ko Y . Microarray Gene-expression Profiling Analysis Comparing PCNSL and Non-CNS Diffuse Large B-Cell Lymphoma. Anticancer Res. 2015; 35(6):3333-40. View

Brunn A, Nagel I, Montesinos-Rongen M, Klapper W, Vater I, Paulus W . Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYC(low)BCL2 (low) subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas. Acta Neuropathol. 2013; 126(4):603-5. DOI: 10.1007/s00401-013-1169-7. View

Johnson N, Slack G, Savage K, Connors J, Ben-Neriah S, Rogic S . Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012; 30(28):3452-9. PMC: 3454768. DOI: 10.1200/JCO.2011.41.0985. View

Rubenstein J, Hsi E, Johnson J, Jung S, Nakashima M, Grant B . Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013; 31(25):3061-8. PMC: 3753699. DOI: 10.1200/JCO.2012.46.9957. View

He M, Zuo C, Wang J, Liu J, Jiao B, Zheng J . Prognostic significance of the aggregative perivascular growth pattern of tumor cells in primary central nervous system diffuse large B-cell lymphoma. Neuro Oncol. 2013; 15(6):727-34. PMC: 3661096. DOI: 10.1093/neuonc/not012. View

DHaene N, Catteau X, Maris C, Martin B, Salmon I, Decaestecker C . Endothelial hyperplasia and endothelial galectin-3 expression are prognostic factors in primary central nervous system lymphomas. Br J Haematol. 2007; 140(4):402-10. DOI: 10.1111/j.1365-2141.2007.06929.x. View

10.

Gregory M, Hann S . c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol. 2000; 20(7):2423-35. PMC: 85426. DOI: 10.1128/MCB.20.7.2423-2435.2000. View

11.

Psathas J, Doonan P, Raman P, Freedman B, Minn A, Thomas-Tikhonenko A . The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop. Blood. 2013; 122(26):4220-9. PMC: 3868926. DOI: 10.1182/blood-2012-12-473090. View

12.

Braaten K, Betensky R, de Leval L, Okada Y, Hochberg F, Louis D . BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res. 2003; 9(3):1063-9. View

13.

Deckert M, Montesinos-Rongen M, Brunn A, Siebert R . Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice. Acta Neuropathol. 2013; 127(2):175-88. DOI: 10.1007/s00401-013-1202-x. View

14.

Dang C . MYC on the path to cancer. Cell. 2012; 149(1):22-35. PMC: 3345192. DOI: 10.1016/j.cell.2012.03.003. View

15.

Meyer N, Penn L . Reflecting on 25 years with MYC. Nat Rev Cancer. 2008; 8(12):976-90. DOI: 10.1038/nrc2231. View

16.

Takeuchi H, Matsuda K, Kitai R, Sato K, Kubota T . Angiogenesis in primary central nervous system lymphoma (PCNSL). J Neurooncol. 2007; 84(2):141-5. DOI: 10.1007/s11060-007-9363-x. View

17.

Gonzalez-Aguilar A, Idbaih A, Boisselier B, Habbita N, Rossetto M, Laurenge A . Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res. 2012; 18(19):5203-11. DOI: 10.1158/1078-0432.CCR-12-0845. View

18.

Hattab E, Martin S, Al-Khatib S, Kupsky W, Vance G, Stohler R . Most primary central nervous system diffuse large B-cell lymphomas occurring in immunocompetent individuals belong to the nongerminal center subtype: a retrospective analysis of 31 cases. Mod Pathol. 2009; 23(2):235-43. DOI: 10.1038/modpathol.2009.164. View

19.

Salghetti S, Kim S, Tansey W . Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. EMBO J. 1999; 18(3):717-26. PMC: 1171164. DOI: 10.1093/emboj/18.3.717. View

20.

Sugita Y, Takase Y, Mori D, Tokunaga O, Nakashima A, Shigemori M . Endoglin (CD 105) is expressed on endothelial cells in the primary central nervous system lymphomas and correlates with survival. J Neurooncol. 2006; 82(3):249-56. DOI: 10.1007/s11060-006-9281-3. View